Stock Ratings / Health Care / LXRX / earnings

ABUS (22) IMMX (33) ANL (52) BCAX (45) ⌘ Pro Terminal →

Lexicon Pharmaceuticals Inc. (LXRX) Next Earnings Date & Expected ±11.6% Move

Q: When is LXRX's next earnings date?

Based on SEC filing cadence, Lexicon Pharmaceuticals Inc. (LXRX)'s next quarterly reporting window is estimated around Dec 30, 2026.

Q: How much is LXRX stock expected to move on earnings?

Volatility modeling currently projects a ±11.6% event move for LXRX, spanning a range between $1.31 and $1.65.

$1.48 -0.34% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Lexicon Pharmaceuticals Inc. (LXRX) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $658.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-8.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LXRX)Realized 20D OHLCV Swing Band: ±11.6%

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±11.6% Swing Band

±$0.17 Expected Swing

MODEL EARNINGS SETUP GAUGE

LXRX Quantitative Pre-Earnings Setup: 39/100

Trailing EPS: $4.25 • YoY Revenue Growth: 180%

Model Bullish Setup (39/100)Model Risk Weight (61/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$49.8M	-$50.3M	-$67.9M	98%
FY 2024	2024-12-31	$6.0M	-$200.4M	-$179.8M	89.7%
FY 2023	2023-12-31	$1.1M	-$177.1M	-$161.9M	92%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LXRX)

✓Walkthrough of LXRX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LXRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -8.07%▼ DESCENDING CHANNEL

2026-10-30O $1.47H $1.50L $1.38C $1.48VOL 2.44M

RES: $2.13SUP: $1.32SMA50: $1.89SMA200: $1.88

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LXRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LXRX Butterfly Map → + Track LXRX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LXRX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LXRX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LXRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LXRX)

Health Care Rank #666 of 1016 ⚔️ ABUS vs LXRX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LXRX vs. ABUS, IMMX, ANL, BCAX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Lexicon Pharmaceuticals Inc. (LXRX) ranks #666 by composite RQD confidence (39/100, grade D-) and #408 by equity capitalization ($658.5M). Within this direct 5-issuer industry benchmark cohort, LXRX leads on earnings valuation at N/A trailing P/E, while LXRX leads on capital efficiency and profitability with -31.5% ROIC and 96.0% gross margin. ANL currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with LXRX at 39/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LXRX ACTIVE Lexicon Pharmaceuticals Inc.	D-	39/100	—	96.0%	-31.5%	-0.34%	$658.5M	Benchmark Subject
ABUS Arbutus Biopharma Corporation	E	22/100	—	—	-35.0%	-0.93%	$656.0M	/abus-vs-lxrx →
IMMX Immix Biopharma Inc.	E	33/100	—	—	-35.0%	-1.78%	$661.6M	/immx-vs-lxrx →
ANL Adlai Nortye Group Ltd.	D+	52/100	—	—	—	+0.78%	$662.0M	/anl-vs-lxrx →
BCAX Bicara Therapeutics Inc.	D	45/100	—	—	-35.0%	-0.31%	$643.9M	/bcax-vs-lxrx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001062822

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Lexicon Pharmaceuticals Inc. (LXRX) reported GAAP revenue of $49.8M (+729.9% vs. FY2024 revenue of $6.0M , and +4386.8% cumulative change since FY2023) , GAAP net income of -$50.3M, operating cash flow of -$67.9M, and free cash flow of -$67.9M (+62.3% YoY). On the balance sheet, LXRX closed FY2025 with $185.0M in total assets against $49.4M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$49.8M	-$50.3M	-$67.9M	-$67.9M	$185.0M	$49.4M
FY2024 (FY)	2024-12-31	$6.0M	-$200.4M	-$178.8M	-$179.8M	$298.4M	$100.3M
FY2023 (FY)	2023-12-31	$1.1M	-$177.1M	-$161.9M	-$161.9M	—	—

3. LXRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LXRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $1.48 (-0.34% 1D, market cap $658.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, LXRX ranks #666 in composite RQD confidence.

How does LXRX compare to ABUS and IMMX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LXRX carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -31.5%. By comparison, ABUS (Arbutus Biopharma Corporation) holds a E grade (22/100 RQD, P/E N/A, ROIC -35.0%, cap $656.0M) and IMMX (Immix Biopharma Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $661.6M). Among the 5-stock peer group, LXRX leads on earnings multiple (N/A) while LXRX leads on capital efficiency (-31.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LXRX?

Per LXRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001062822), Lexicon Pharmaceuticals Inc. generated $49.8M in revenue (+729.9% YoY), -$50.3M in net income, and -$67.9M in free cash flow against $185.0M in total assets and $49.4M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LXRX trading relative to its 50-day, 200-day, and 52-week technical levels?

LXRX last traded at $1.48 (-0.34% on volume of 1,772,659 shares), positioning the stock -21.69% below its 50-day simple moving average ($1.89) and -21.28% below its 200-day simple moving average ($1.88). Across its 52-week range of $1.10 to $2.68, LXRX sits at the 24.1% percentile with a 14-day RSI of 29.1 (OVERSOLD (<32)) and an implied next-earnings move of ±11.6% ($1.31 to $1.65).

LXRX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is LXRX's next earnings date?

Based on SEC filing cadence, Lexicon Pharmaceuticals Inc. (LXRX)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is LXRX stock expected to move on earnings?

Volatility modeling currently projects a ±11.6% event move for LXRX, spanning a range between $1.31 and $1.65.

Direct Sub-Reports: LXRX RQD Cockpit LXRX 12M Forecast LXRX Earnings & Move LXRX Dividends & DRIP LXRX Insiders & 13F LXRX Whale Options LXRX Profit Sankey LXRX News & Why